All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 15 November 2018, brentuximab vedotin, an anti-CD30 monoclonal antibody attached via a protease-cleavable linker to a microtubule-disrupting agent, was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone).
The Breakthrough Therapy Designation granted by the FDA was based on the positive results obtained from the randomized, double-blind, placebo-controlled phase III ECHELON-2 trial (NCT01777152) assessing brentuximab vedotin in combination with CHP versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) alone, as a frontline therapy in patients with CD30-expressing PTCL.
The phase III ECHELON-2 study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) of brentuximab vedotin in combination with CHP versus CHOP as assessed by an Independent Review Facility (IRF; HR = 0.71, P = 0.0110). In addition, brentuximab vedotin plus CHP led to a superior overall survival compared to standard CHOP chemotherapy (HR = 0.66, P = 0.0244) in the treatment of CD30-expressing PTCL.
According to the drug manufacturers, this is the third Breakthrough Therapy Designation granted for brentuximab vedotin, which they say “supports their goal to make this therapy available to patients with newly diagnosed peripheral T-cell lymphomas as soon as possible.”
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox